The transformed phenotype of rat FE-8 cells transfected by an activated human HRAS gene was suppressed upon fusion with normal cells. An experimental approach was developed to identify and isolate a human gene capable of suppressing the transforming activity of the HRAS oncogene in FE-8 cells. Genomic DNA from human placenta was introduced into FE-8 cells by cotransfection with the plasmid pY3 conferring hygromycin B resistance. Transfectants were selected in medium containing hygromycin B. HRAS-transformed FE-8 cells showed an increased sensitivity toward ouabain when compared to their normal counterparts. Therefore, the population of transfected hygromycin B-resistant cells was treated with ouabain to eliminate cells with a transformed phenotype. Ouabain selection resulted in a small number of cell clones exhibiting a more normal phenotype. The clones had lost the morphology of transformed cells and required anchorage for growth. The tumorigenicity of transfectants in nude mice was reduced but not completely abol- 
ABSTRACT
The transformed phenotype of rat FE-8 cells transfected by an activated human HRAS gene was suppressed upon fusion with normal cells. An experimental approach was developed to identify and isolate a human gene capable of suppressing the transforming activity of the HRAS oncogene in FE-8 cells. Genomic DNA from human placenta was introduced into FE-8 cells by cotransfection with the plasmid pY3 conferring hygromycin B resistance. Transfectants were selected in medium containing hygromycin B. HRAS-transformed FE-8 cells showed an increased sensitivity toward ouabain when compared to their normal counterparts. Therefore, the population of transfected hygromycin B-resistant cells was treated with ouabain to eliminate cells with a transformed phenotype. Ouabain selection resulted in a small number of cell clones exhibiting a more normal phenotype. The clones had lost the morphology of transformed cells and required anchorage for growth. The tumorigenicity of transfectants in nude mice was reduced but not completely abol- Tumorigenicity and anchorage-independent proliferation are frequently suppressed in somatic cell hybrids between tumorigenic cell lines and normal diploid cells. From these findings and the consistent detection of chromosome deletions in human hereditary tumors, the hypothesis has emerged that mutation, deletion, or rearrangements of tumor suppressor genes (recessive oncogenes or "anti-oncogenes") contribute to the conversion of a normal cell to the malignant state (for review, see refs. [1] [2] [3] [4] [5] . These genetic alterations might be cooperative with the activation of dominantly acting oncogenes (6) . It has been proposed that normal cellular growth control is reestablished in a tumor-normal cell hybrid because the functions of inactivated genes of the tumor cell are restored by genes of the normal parental cell (1) (2) (3) (4) (5) . The normal phenotype in tumor-normal hybrids predominates even during the continued expression of transforming RAS genes (7) (8) (9) . Genetic analysis of suppressed cellular hybrids and of tumorigenic segregants derived from them permitted the assignment of putative suppressor genes to specific human or rodent chromosomes (for review, see refs. 1 and 2). Recently, results from segregation analysis of human intraspecies hybrids were confirmed by microcell transfer experiments. Introduction of human chromosome 11 via microcell fusion into tumorigenic HeLa cells and into a Wilms tumor cell line resulted in the abrogation of tumorigenicity (10, 11) . It is desirable to advance these studies to the molecular level and identify and characterize the genes capable of reverting the neoplastic phenotype. The use of microcell fusion or of whole-cell fusion does not allow the access to molecular clones of suppressor genes.
We established a functional assay leading to identification and molecular cloning of DNA sequences involved in genetic suppression of neoplastic transformation. Genomic DNA was prepared from normal human placenta and was transfected together with a dominant selectable hph gene (12) onto a rat cell line transformed by an activated human HRAS gene. Cotransfectants were selected in two subsequent procedures. The antibiotic hygromycin B (HMB) was used to select a cell population of several thousand individually transfected cell clones. HMB-resistant cells were subjected to treatment with ouabain to isolate cell clones that had acquired the normal (transformation-suppressed) phenotype after incorporation of donor DNA sequences. This selection is based on the increased sensitivity of RAS-transformed cells toward ouabain when compared to their normal counterparts (13 (Geneticin; GIBCO) at 400 pgg/ml. These cells contain four or five copies of the transforming HRAS gene (9) . Cells were grown in Dulbecco's modified Eagle's medium (DMEM; GIBCO) supplemented with 10% fetal calf serum, penicillin (100 units/ml), and streptomycin (100 pug/ml) (standard medium). All cells were tested for mycoplasma contamination and were found to be negative.
DNA Transfection and Selection of Transfectants. High molecular weight DNA was prepared from human placenta as described (14) . Cotransfection of human DNA and the plasmid pY3 harboring the HMB-resistance gene (hph) (12) into FE-8 cells was accomplished by calcium phosphate coprecipitation as described by Wigler et al. (15) (17, 18) . The following 32P-labeled probes were used: the 2.9-kb Sac I fragment of pEJ 6.6 (HRAS) (19) , the 1.05-kb Kpn I/Sst I fragment of pY3 (12) , and total human placenta DNA previously sheared to an average size of 5 kb. The oncoprotein p21 was detected by immunoblot analysis of crude membrane preparations as described (20) using a p21-specific rabbit IgG antibody (supplied by R. W. Sweet, Smith, Kline & French, Swedeland, PA). A recombinant phage library was constructed by inserting BamHI-digested DNA prepared from secondary transfectant FS9-7 into the BamHI sites of phage EMBL 3 (21) . The library was screened for the presence of human repetitive DNA and hph sequences by filter hybridization (22) .
RESULTS

Suppression of Transformed Phenotypes in Malignant Rat
Cells by Transfection of DNA from Normal Human Cells.
Transformed FE-8 cells were derived from the phenotypically normal 208F rat cell line after cotransfection of the activated human HRAS-1 gene (EJ-RAS) and plasmid pSV2neo (9 (Fig. 1) . We conclude from these results that the phenotype of a more normal morphology can be transferred from primary to secondary transfectants and stably expressed.
Primary and secondary stable transfectants exhibited reduced cloning efficiencies in agar medium ranging from 2% to <0.001%. The few individual agar colonies contained <200 cells. Proliferation in standard medium on a plastic support was not affected. Transfectants with A97-3 DNA were assayed. The clones were not treated with ouabain after HMB selection. All transfectants appeared to be strongly anchorage dependent (Fig. 5) . Introduction of the hph gene by itself did not abolish the anchorage-independent phenotype of FE-8 cells. We conclude from these results that the human DNA sequence located in the 18-kb BamHI restriction fragment adjacent to the hph gene functions as a suppressor gene for the anchorage-independent proliferation of RAS-transformed FE-8 cells. Further structural analysis of the 18-kb BamHI fragment is needed to define the precise composition, organization, and the transcriptional unit contained within this fragment. The expression of the transforming p21 HRAS oncoprotein was measured in A97-1 and A97-2 transfected cell clones. The anchorage-dependent transfectants maintained a p21 expression (Fig. 2, lanes f-h) . This (27, 28) expression. Rather, the suppressor gene appears to act either at a distant step in the series of molecular events originated by the activated RAS oncogene (RAS-induced signaling pathway) or in a cellular pathway that is functionally independent of RAS gene action. RAS proteins appear to play an essential role in the transfer of signals to cytoplasmic effectors (for review, see ref. 29) . Therefore, specific inhibitors of RAS protein function would aid in defining individual steps in the signaling pathway and in identifying target molecules. The elucidation of a specific RASinhibitory function requires identification of the protein product encoded by the suppressor gene isolated in this study.
The retinoblastoma susceptibility gene and a recessive oncogene in Drosophila have been isolated by chromosome walking techniques (30) (31) (32) . Transfer of the lethal (2) giant larvae gene into Drosophila mutants resulted in a hereditary suppression of neuroblastoma formation (33) . No tumorsuppressing activity has yet been reported for the retinoblastoma gene. DNA-mediated reversion of a spontaneously transformed mouse NIH 3T3 cell clone was described earlier (34) . However, an increase in the frequency of induced reversion exceeding that of spontaneous reversion occurred only after the sixth transfection cycle with unintegrated DNA as the donor, and the reversion-active sequence was not cloned. Recently, Padmanabhan et al. (35) reported a high incidence of growth inhibition in HeLa cells following transfection of DNA from quiescent human cells. We speculate that transfer of DNA from normal cells into different tumorigenic indicator cells and selection for phenotypically normal revertants may provide the basis for detection of multiple recessive oncogenes. Indicator cells harboring a defined transforming gene are preferable to spontaneously transformed recipient cells, since revertants resulting from loss or mutation of the known oncogene can be easily detected and excluded from further analysis. The suppressor gene described in this paper is tightly linked to the hph gene. Thus, suppressing activity can be assayed in any HMBresistant transfectant including tumorigenic human cells. The further characterization of the molecular structure and function of recessive oncogenes will provide insights into tumorigenesis and help to define their role in relation to dominantly acting oncogenes. Analysis of the presence and expression of the suppressor gene described here in human tumors and cell lines and consistent involvement will define its significance for cancer diagnosis and therapy.
